Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Lykos Therapeutics

Recent news which mentions Lykos Therapeutics

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
Tickers CMPS NEWS
Tags Food and Drug Administration (FDA) mental health Top Stories
From Benzinga
Veterans Affairs Eyes Funding For New MDMA-PTSD Trial After FDA Setback
Tickers NEWS
Tags Department of Veterans Affairs Food and Drug Administration Psychedelics
From Benzinga
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Tickers ATAI CMPS DMT MBIO
Tags Psychedelics Food and Drug Administration Benzinga
From Benzinga
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Tickers CMPS NEWS
Tags Psychedelics Michael Mullette Government
From Benzinga
Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
Tickers NEWS
Tags David Hough Psychedelics Rick Dolbin
From Benzinga
MDMA Therapy Papers Retracted Amid Ethical Concerns At Lykos Study Site
Tags Multidisciplinary Association for Psychedelic Studies (MAPS) Cannabis Psychedelic Research
From Benzinga
FDA Rejects MDMA For PTSD Treatment, Calls For More Research On Psychedelic Therapy
Tickers MDMA NEWS
Tags Top Stories News Amy Emerson
From Benzinga
FDA Poised To Make Historic Decision On MDMA Therapy To Treat PTSD: Here's How Things Stand
Tickers MDMA NEWS
Tags Benzinga FDA Food and Drug Administration
From Benzinga
Five Out Of Six Studies On MDMA Show Positive Results, Yet FDA Approval Still Faces Hurdles
Tickers NEWS
Tags Market News Health Care News
From Benzinga
MDMA Therapy For PTSD Closer To Legality As Key FDA Approval Meeting Approaches, Sparking Hope And Controversy
Tickers NEWS
Tags Veterans Administration Multidisciplinary Association for Psychedelic Studies News
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.